Palamedrix, Inc.
https://www.palamedrix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Palamedrix, Inc.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Biosensors
- Chemistry, Immunoassay
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Technologies
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice